Ciloa’s Chikungunya project retained for FUI funding

The Fond Unique Interministériel (FUI) has selected the ChikVax project carried by Ciloa, a biotech Company from Montpellier. The project aims to develop a new generation of virus-free, adjuvant-free vaccines, one of them being a vaccine against Chikungunya.

The budget of ChikVax project is of 2.2 M€ over 36 months. The program involves Ciloa as coordinator and the Inserm, Pasteur institute (Paris) and Calixar company (Avignon) as partners.

More on La Tribune